Section 1: Summary of Clarifications and Rationale

The procedures clarified in this Clarification Memorandum (CM) have been approved by the NIAID Medical Officer and are to be implemented immediately upon issuance. IRB approval of this CM is not required by the sponsor; however, investigators may submit the CM to the IRB overseeing the study at their site for information. This CM is official MTN-015 documentation and is effective immediately. A copy of this CM must be retained in each study site’s Essential Documents file for MTN-015. No change in informed consent is necessitated by or included in this CM.

The primary goal for this CM is to omit references to wet mount to allow for consistency with newer testing methods employed by study sites. Additionally, the Protocol Team Roster is updated.

Section 2: Implementation

Text to be deleted is noted by strikethrough and text to be added is noted below in bold.

1. The following update is made to the Protocol Team Roster that appeared in MTN-015, CM #02, dated 21 August 2008:

   David Humiston  
   Protocol Specialist  
   Microbicide Trials Network  
   204 Craft Avenue  
   Pittsburgh, PA 15213 USA  
   T: 412-641-5579  
   F: 412-641-6170  
   humistondw@mail.magee.edu

2. Reference to wet mount is replaced with testing in the following tables and sections:

   Table 1: Screening and Enrollment Visit, Pelvic Samples.

<table>
<thead>
<tr>
<th>Pelvic Samples</th>
<th>Vaginal pH</th>
<th>Wet Mount-Testing for bacterial vaginosis (BV), Candida, and Trichomonas</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Pap Smear at Selected Sites</td>
</tr>
</tbody>
</table>
Table 2: Month 1 and Month 3 Post-Seroconversion Visits

| Pelvic Samples | *Vaginal pH  
| *Wet Mount Testing for BV, Candida, and Trichomonas  
| */† Pap Smear at Selected Sites |

Table 3: Month 6 and Q6 Months Post-Seroconversion Visits

| Pelvic Samples | */**Vaginal pH  
| */**Wet Mount Testing for BV, Candida and Trichomonas  
| */† Pap Smear at Selected Sites (annually) |

If indicated; */**Urine SDA for Chlamydia and Gonorrhea, Syphilis Serology, Vaginal pH, and Wet Mount testing for BV, Candida, and Trichomonas should be performed at visits annually, with performance of these measures at additional scheduled visits as clinically indicated; */PAP smears should be done at 6 month intervals in the first year after seroconversion, and then annually if the initial tests are negative.

Table 4: Week 2, Month 1, and Month 3 after Initiation of ART

| Pelvic Samples | *Vaginal pH  
| *Wet Mount Testing for BV, Candida, and Trichomonas  
| */† Pap Smear at Selected Sites |

Table 5: Month 6 and Q6 Months Visits After Initiation of ART

| Pelvic Samples | */**Vaginal pH  
| */**Wet Mount Testing for BV, Candida and Trichomonas  
| */† Pap Smear at Selected Sites |

If indicated; */**Urine SDA for Chlamydia and Gonorrhea, Syphilis Serology, Vaginal pH, and Wet Mount testing for BV, Candida, and Trichomonas should be performed at visits annually, with performance of these measures at other scheduled visits as clinically indicated; */PAP smears should be done at 6 month intervals in the first year after seroconversion, and then annually if the initial tests are negative.

Table 6: Final Visit

| Pelvic Samples | Vaginal pH  
| Wet Mount Testing for BV, Candida and Trichomonas  
| */† Pap Smear at Selected Sites |

Section 7.5.1, Local Laboratory Specimens, Pelvic Samples, first paragraph:

Vaginal pH testing and wet mount testing for bacterial vaginosis, candidiasis and trichomoniasis will be conducted at the sites by clinical and/or laboratory staff who have established proficiency in these procedures per MTN policies and procedures.

Appendix I: Schedule of Study Visits and Evaluations

| Wet Mount Testing for BV, Candida, Trichomonas | X | ▲ | ▲ | ▲ (Annual) | ▲ | ▲ (Annual) | X |